Rad 140 Magnus

Catalogue entry: Rad 140 Magnus. Labelled content: 10 mg/tablet. Listed pack: 60 tablets. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

RAD-140 is a nonsteroidal androgen-receptor modulator investigated in preclinical models and early human oncology research. Its experimental receptor activity is the reason it appears alongside other SARMs. A common catalogue category does not make its safety profile interchangeable with Ostarine or Ligandrol.

What the research measured

LoRusso and colleagues published a first-in-human phase I study in Clinical Breast Cancer in 2022. Participants had advanced hormone-receptor-positive breast cancer. The study explored safety, pharmacokinetics and antitumour activity in that clinical setting. It was not designed to assess strength, recovery, fat loss or sporting performance in healthy consumers.

Sporting claims and limitations

Sporting discussions often interpret androgen-receptor activity as a promise of useful muscle gain. Receptor activity alone cannot establish that outcome. The oncology study reported adverse events including elevations in liver enzymes. Results in patients with cancer do not quantify risk for healthy users, while a lack of relevant long-term data should remain an uncertainty rather than reassurance.

Product identity and documentation

For the product presented here, verify the substance name, selected content and physical presentation separately from research claims. Analytical documentation should link the actual lot to an identity result and a clearly described method. Findings for a trial formulation cannot validate an unrelated bottle, its capsule content or a multi-compound combination. No sporting-use protocol follows from these product notes.